Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs
21 June 2021 - 4:00PM
Tiziana Life Sciences plc (NASDAQ: TLSA, LSE:
TILS), a biotechnology company focused on innovative therapeutics
for oncology, neurology, inflammation and infectious diseases, is
pleased to announce the appointment of Dr. Kevin Schutz, PharmD, as
Vice-President of Regulatory Affairs. Dr. Schutz will lead
regulatory interactions related to clinical studies in the United
States, Europe and Asian countries.
Dr. Schutz has over 19 years of pharmaceutical industry
experience including 14 years of Regulatory Affairs experience. He
has focused on disease indications with high unmet medical needs,
in Neurology (including multiple sclerosis), Pulmonology (including
infectious disease), and other potential disease indications, which
the Company is currently developing products for or is planning to
pursue. Specifically, Foralumab (an intranasally delivered, next
generation, fully human anti-CD3 monoclonal antibody) for Secondary
Progressive Multiple Sclerosis (SPMS) and COVID-19 with Pulmonary
Inflammation as lead indications.
“Dr. Schutz brings extensive hands-on experience working with
regulatory agencies including the FDA (USA), EMA (Europe), and PMDA
(Japan), among others. His background will greatly strengthen
Tiziana’s global development capabilities in regions where the
Company is actively pursuing clinical development. We are pleased
to have him on our team to lead this important role in global
development of our pipeline,” commented Dr. Neil Graham, Chief
Medical Officer of Tiziana Life Sciences.
“I am excited to join the Tiziana team to further the
development of products which aim to help patients manage diseases
with an unmet medical need. Tiziana’s lead pipeline candidate,
Foralumab, is promising with multiple potential indications in
multiple sclerosis and pulmonary diseases and I look forward to
contributing to its development,” said Dr. Schutz.
About Tiziana Life Sciences
Tiziana Life Sciences plc (NASDAQ: TLSA, LSE:
TILS) is a UK biotechnology company that focuses on the discovery
and development of novel molecules to treat human disease in
oncology and immunology. In addition to Milciclib (a CDK inhibitor
being developed in oncology), the Company is also developing
Foralumab in COVID-19, multiple sclerosis, and Crohns Disease.
Foralumab is the only second generation fully human anti-CD3
monoclonal antibody in clinical development in the world. This
Phase 2 compound has potential application in a wide range of
autoimmune and inflammatory diseases, such as nonalcoholic
steatohepatitis (NASH), ulcerative colitis, multiple sclerosis,
type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid
arthritis, where modulation of a T-cell response is desirable. The
Company is accelerating development of anti-Interleukin 6 receptor
(IL6R) mAb, a fully human monoclonal antibody for treatment of
IL6-induced inflammatory pulmonary diseases.
Forward-Looking Statements
Certain statements made in this announcement are
forward-looking statements. These forward-looking statements are
not historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its
beliefs; and assumptions. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements.
These statements are not guarantees of future performance and are
subject to known and unknown risks, uncertainties, and other
factors, some of which are beyond the Company's control, are
difficult to predict, and could cause actual results to differ
materially from those expressed or forecasted in the
forward-looking statements. The Company cautions security holders
and prospective security holders not to place undue reliance on
these forward-looking statements, which reflect the view of the
Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
For further enquiries: |
|
|
|
United Kingdom: |
|
|
|
Tiziana Life Sciences plc |
|
|
|
Gabriele Cerrone, Chairman and founder |
+44 (0)20
7495 2379 |
|
|
United States:Investors:Dave Gentry, CEORedChip Companies
Inc.dave@redchip.com |
407-491-4498 |
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Jul 2023 to Jul 2024